NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsCarl Maximilian Thielmann, Klaus Griewank, Philipp Jansen et al.|European Journal of Cancer|2021Cited by 33
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyCarl Maximilian Thielmann, Klaus Griewank, Johanna Matull et al.|European Journal of Cancer|2021Cited by 20
Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanomaJohanna Matull, Klaus Griewank, Jan‐Malte Placke et al.|Frontiers in Immunology|2024Cited by 11